Combining TACE with immunotherapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial looks at whether adding a procedure called TACE to standard immunotherapy (Atezolizumab plus Bevacizumab) works better for people with liver cancer that cannot be removed by surgery. It aims to create a model to predict who benefits most from this combination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with liver cancer that cannot be surgically removed
- You are starting or have recently had treatment with Atezolizumab and Bevacizumab
- You are able to have TACE (a procedure that blocks blood flow to the tumor) around the time of your immunotherapy
- You have at least one tumor that has not been treated before
- You are in good enough health to be up and about (ECOG score 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
This trial is testing a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus a procedure called TACE (chemoembolization) against a targeted therapy pill (lenvatinib) plus TACE for people with advanced liver cancer. The goal is to see which approach works better to shrink tumors and improve outcomes.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.